Virus-based nanoparticles (VNPs): Platform technologies for diagnostic imaging

Advanced Drug Delivery Reviews

Volumn 58, Issue 14, 2006, Pages 1505-1522

  Manchester, Marianne ^a   Singh, Pratik ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CPMV; Imaging; Nanoparticle; Nanotechnology; Tumor; Vascular; Virus; VNP

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; MEDICAL IMAGING; NANOTECHNOLOGY; PATIENT TREATMENT; VIRUSES;

LIPOSOMES; NONINVASIVE IMAGING; PARAMAGNETIC NANOPARTICLES;

NANOSTRUCTURED MATERIALS;

DOXORUBICIN; FOLIC ACID; HEAT SHOCK PROTEIN; MACROGOL; PACLITAXEL; PEPTIDE DERIVATIVE; TRANSFERRIN;

BACTERIOPHAGE M13; BIOCOMPATIBILITY; CANCER; CARDIOVASCULAR DISEASE; CONJUGATION; COWPEA; DIAGNOSTIC IMAGING; DOG; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNOGENICITY; IN VIVO STUDY; MAIZE CHLOROTIC MOTTLE; MOSAIC VIRUS; MS2 VIRUS; MUTAGENESIS; NANOPARTICLE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARVOVIRUS; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY; TOXICITY; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE;

ANIMALS; COMOVIRUS; DIAGNOSTIC IMAGING; HUMANS; NANOMEDICINE; NANOPARTICLES;

EID: 33751534216     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.09.014     Document Type: Review

References (129)

1. Graves E.E., Weissleder R., and Ntziachristos V. Fluorescence molecular imaging of small animal tumor models. Curr. Mol. Med. 4 (2004) 419-430
2. Rudin M., and Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2 (2003) 123
3. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., Chinen L.K., Fuhrhop R.W., Scherrer D.E., and Wickline S.A. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106 (2002) 2842-2847
4. Quintana A., Raczka E., Piehler L., Lee I., Myc A., Majoros I., Patri A.K., Thomas T., Mule J., and Baker Jr. J.R. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19 (2002) 1310-1316
5. Winter P.M., Caruthers S.D., Kassner A., Harris T.D., Chinen L.K., Allen J.S., Lacy E.K., Zhang H., Robertson J.D., Wickline S.A., and Lanza G.M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel avb3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res. 63 (2003) 5838-5843
6. Clark H.A., Hoyer M., Philbert M.A., and Kopelman R. Optical nanosensors for chemical analysis inside single living cells. 1. Fabrication, characterization, and methods for intracellular delivery of PEBBLE sensors. Anal. Chem. 71 (1999) 4831-4836
7. Kelly K., Alencar H., Funovics M., Mahmood U., and Weissleder R. Detection of invasive colon cancer using a novek, targeted, library derived fluorescent peptide. Cancer Res. 64 (2004) 6247-6251
8. Ruoslahti E. Specialization of tumor vasculature. Nat. Rev., Cancer 2 (2002) 83-90
9. Nanda A., and St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 16 (2004) 44-49
10. Arap W., Haedicke W., Bernasconi M., Kain R., Rajotte D., Krajewski S., Ellerby H.M., Bredesen d.E., Pasqualini R., and Ruoslalhti E. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1527-1531
11. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov. Today 7 (2002) 1138-1143
12. Hood J., Bednarski M., Frausto R., Guccione S., Reisfeld R., Xiang R., and Cheresh D. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
13. Garlanda C., and Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1193-1202
14. An P., Lei H., Zhang J., Song S., He L., Jin G., Liu X., Wu J., Meng L., Liu M., and Shou C. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int. J. Cancer 111 (2004) 165-173
15. Binetruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouet J., Derbin C., Perret G., and Mazie J.C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19 (2000) 1525-1533
16. Liu C., Bhattacharjee G., Boisvert W., Dilley R., and Edgington T. In vivo interrogation of the molecular display of atherosclerotic lesion surfaces. Am. J. Pathol. 163 (2003) 1859
17. Molenaar T., Twist J., deHaas S., Peterse N., Vogelaar B., Kuiper J., and Biessen E. P-selectin as a candidate target in atherosclerosis. Biochem. Pharmacol. 66 (2003) 859-866
18. Houston P., Goodman J., Lewis A., Campbell C., and Braddock M. Homing markers for atherosclersis: applications for drug delivery, gene delivery and vascular imaging. FEBS Lett. 492 (2001) 73-77
19. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
20. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., and Ruoslahti E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12617-12621
21. Portney N.G., Singh K., Chaudhary S.K., Stephens J., Destito G., Schneemann A., Manchester M., and Ozkan M. Organic and inorganic nanoparticle hybrids. Langmuir 21 (2005) 2098-2103
22. Voura E.B., Jaiswal J.K., Mattoussi H., and Simon S.M. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat. Med. 10 (2004) 993-998
23. Sullivan D.C., and Ferrari M. Nanotechnology and tumor imaging: seizing an opportunity. Mol. Imaging Neurosci. 3 (2004) 364-369
24. Feng S.S., Mu L., Win K.Y., and Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11 (2004) 413-424
25. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev., Cancer 5 (2005) 161-171
26. Guccioine S., Li K.C., and Bednarski M.D. Vascular-targeted nanoparticles for molecular imaging and therapy. Methods Enzymol. 386 (2004) 219-236
27. Guccioine S., Li K.C., and Bednarski M.D. Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents. IEEE Eng. Med. Biol. Mag. 23 (2004) 50-56
28. Jiang W., Papa E., Fischer H., Mardyani S., and Chan W.C. Semiconductor quantum dots as contrast agents for whole animal imaging. Trends Biotechnol. 22 (2004) 607-609
29. Moffat B.A., Reddy G.R., McConville P., Hall D.E., Chenevert T.L., Kopelman R.R., Philbert M., Weissleder R., Rehemtulla A., and Ross B.D. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol. Imaging Neurosci. 2 (2003) 324-332
30. Singh P., Gonzalez M.J., and Manchester M. Viruses and their uses in nanotechnology. Drug Dev. Res. 67 (2006) 23-41
31. Peabody D.S. A viral platform for chemical modification and multivalent display. J. Nanobiotechnol. 1 (2003) 5
32. Mao C., Solis D.J., Reiss B.D., Kottmann S.T., Sweeney R.Y., Hayhurst A., Georgiou G., Iverson B., and Belcher A.M. Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires. Science 303 (2004) 213-217
33. Mao C., Flynn C.E., Hayhurst A., Sweeney R.Y., Qi J., Georgiou G., Iverson B., and Belcher A.M. Viral assembly of oriented quantum dot nanowires. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6946-6951
34. Lee S.-W., Mao C., Flynn C.E., and Belcher A.M. Ordering of quantum dots using genetically engineered viruses. Science 296 (2002) 892-895
35. Kickhoefer V.A., Garcia Y., Mikyas Y., Johansoon E., Zhou J.C., Raval-Fernandes S., Monoofar P., Zink J.I., Dunn B., Stewart P.L., and Rome L.H. Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4248-4252
36. Yamada T., Ueda M., Seno M., Kondo A., Tanizawa K., and Kuroda S. Novel tissue and cell type-specific gene/drug delivery system using surface engineered hepatitis B virus nano-particles. Curr. Drug Targets Infect. Disord. 4 (2004) 163-167
37. Flenniken M.L., Willits D., Harmsen A.L., Liepold L.O., Harmsen A.J., Young M.J., and Douglas T. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem. Biol. 13 (2006) 161-170
38. Khor I.W., Lin T., Langedijk J.P., Johnson J.E., and Manchester M. Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. J. Virol. 76 (2002) 4412-4419
39. Chatterji A., Burns L.L., Taylor S.S., Lomonossoff G.P., Johnson J.E., Lin T., and Porta C. Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials. Intervirology 45 (2002) 362-370
40. Brennan F.R., Jones T.D., and Hamilton W.D. Cowpea mosaic virus as a vaccine carrier of heterologous antigens. Mol. Biotechnol. 17 (2001) 15-26
41. Gupta S.S., Kuzelka J., Singh P., Lewis W.G., Manchester M., and Finn M.G. Accelerated bioorthogonal cojugation: a practical method for ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug. Chem. 16 (2005) 1572-1579
42. van Lent J., Storms M., van der Meer F., Wellink J., and Goldbach R. Tubular structures involved in movement of cowpea mosaic virus are also formed in infected cowpea protoplasts. J. Gen. Virol. 72 Pt 11 (1991) 2615-2623
43. Silva M.S., Wellink J., Goldbach R.W., and van Lent J.W. Phloem loading and unloading of Cowpea mosaic virus in Vigna unguiculata. J. Gen. Virol. 83 (2002) 1493-1504
44. Dessens J.T., and Lomonossoff G.P. Cauliflower mosaic virus 35S promoter-controlled DNA copies of cowpea mosaic virus RNAs are infectious on plants. J. Gen. Virol. 74 (1993) 889-892
45. Porta C., Spall V., Loveland J., Johnson J., Barker P., and Lomonossoff G. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 202 (1994) 949-955
46. Wang Q., Kaltgrad E., Lin T., Johnson J., and Finn M. Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem. Biol. 9 (2002)
47. Wang Q., Lin T., Johnson J., and Finn M. Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem. Biol. 9 (2002) 813-819
48. Chatterji A., Ochoa W., Shamieh L., Salakian S.P., Wong S.M., Clingon G., Ghosh P., Lint T., and Johnson J. Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug. Chem. 15 (2004) 807-813
49. Wang Q., Chan T.R., Hilgraf R., Fokin V.V., Sharpless K.B., and Finn M.G. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125 (2003) 3192-3193
50. Sen Gupta S., Kuzelka J., Singh P., Lewis W.G., Manchester M., and Finn M.G. Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug. Chem. 16 (2005) 1572-1579
51. Chatterji A., Ochoa W., Paine M., Ratna B.R., Johnson J.E., and Lin T. New Addresses on an addressable virus nanoblock: uniquely reactive lys residues on cowpea mosaic virus. Chem. Biol. 11 (2004) 855-863
52. Ahlquist P. Bromovirus RNA replication and transcription. Curr. Opin. Genet. Dev. 2 (1992) 71-76
53. Douglas T., and Young M.J. Host-guest encapsulation of materials by assembled virus protein cages. Nature 393 (1998) 152-155
54. Krishna N.K., Marshall D., and Schneemann A. Analysis of RNA packaging in wild-type and mosaic protein capsids of flock house virus using recombinant baculovirus vectors. Virology 305 (2003) 10-24
55. Speir J.A., Munshi S., Wang G., Baker T.S., and Johnson J.E. Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and cryo electron microscopy. Structure 3 (1995) 63-78
56. Zhao X., Fox J.M., Olson N.H., Baker T.S., and Young M.J. In vitro assembly of cowpea chlorotic mottle virus from coat protein expressed in Escherichia coli and in vitro-transcribed viral cDNA. Virology 207 (1995) 486-494
57. Brumfield S., Willits D., Tang L., Johnson J.E., Douglas T., and Young M. Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J. Gen. Virol. 85 (2004) 1049-1053
58. Speir J.A., Bothner B., Qu C., Willits D.A., Young M.J., and Johnson J.E. Enhanced local symmetry interactions globally stabilize a mutant virus capsid that maintains infectivity and capsid dynamics. J. Virol. 80 (2006) 3582-3591
59. Valegård K., Liljas L., Fridborg K., and Unge T. The three-dimensional structure of the bacterial virus MS2. Nature (London) 345 (1990) 36-41
60. Cargile B.J., McLuckey S.A., and Stephenson J.L.J. Identification of bacteriophage MS2 coat protein from E. coli lysates via ion trap collisional activation of intact protein ions. Anal. Chem. 73 (2001) 1277-1285
61. Hooker J.M., Kovacs E.W., and Francis M.B. Interior surface modification of bacteriophage MS2. J. Am. Chem. Soc. 126 (2004) 3718-3719
62. Brown W.L., Mastico R.A., Wu M., Heal K.G., Adams C.J., Murray J.B., Simpson J.C., Lord J.M., Taylor-Robinson A.W., and Stockley P.G. RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45 (2002) 371-380
63. Marvin D.A., Hale R.D., Nave C., and Helmer-Citterich M. Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe. J. Mol. Biol. 235 (1994) 260-286
64. Schlick T.L., Ding Z., Kovacs E.W., and Francis M.B. Dual-surface modification of the tobacco mosaic virus. J. Am. Chem. Soc. 127 (2005) 3718-3723
65. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (1985) 1315-1317
66. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev., Cancer 2 (2002) 83-90
67. Rae C.S., Khor I.W., Wang Q., Destito G., Gonzalez M.J., Singh P.R., Thomas D., Estrada M.N., Powell E., Finn M.G., and Manchester M. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343 (2005) 224-235
68. Neutra M.R., Frey A., and Kraehenbuhl J.-P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86 (1996) 345-348
69. Selling B.H., Allison R.F., and Kaesberg P. Genomic RNA of an insect virus directs synthesis of infectious virions in plants. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 434-438
70. Johnson K.L., and Ball L.A. Replication of flock house virus RNAs from primary transcripts made in cells by RNA polymerase II. J. Virol. 71 (1997) 3323-3327
71. Price B.D., Rueckert R.R., and Ahlquist P. Complete replication of an animal virus and maintenance of expression vectors derived from it in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9465-9470
72. Langeveld J.P., Brennan F.R., Martinez-Torrecuadrada J.L., Jones T.D., Boshuizen R.S., Vela C., Casal J.I., Kamstrup S., Dalsgaard K., Meloen R.H., Bendig M.M., and Hamilton W.D. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine 19 (2001) 3661-3670
73. Lewis J.D., Destito G., Zjilstra A., Gonzalez M.J., Quigley J., Manchester M., and Stuhlmann H. Viral nanoparticles (VNPs) as tools for intravital vascular imaging. Nat. Med. 12 (2006) 354-360
74. Raja K.S., Wang Q., Gonzalez M.J., Manchester M., Johnson J.E., and Finn M.G. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4 (2003) 472-476
75. Bertens P., Wellink J., Goldbach R., and van Kammen A. Mutational analysis of the cowpea mosaic virus movement protein. Virology 276 (2000) 199-208
76. Basu G., Allen M., Willits D., Young M., and Douglas T. Metal binding to cowpea chlorotic mottle virus using terbium(III) fluorescence. J. Biol. Inorg. Chem. 8 (2003) 721-725
77. Allen M., Bulte J.W., Liepold L., Basu G., Zywicke H.A., Frank J.A., Young M., and Douglas T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn. Reson. Med. 54 (2005) 807-812
78. Baluk P., Hashizume H., and McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15 (2005) 102-111
79. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., and McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156 (2000) 1363-1380
80. Nagayasu A., Uchiyama K., and Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 40 (1999) 75-87
81. Tabata Y., Murakami Y., and Ikada Y. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Release 50 (1998) 123-133
82. Gomme P.T., McCann K.B., and Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov. Today 10 (2005) 267-273
83. Inoue T., Cavanaugh P.G., Steck P.A., Brunner N., and Nicolson G.L. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J. Cell. Physiol. 156 (1993) 212-217
84. Bridges K.R., and Smith B.R. Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. J. Clin. Invest. 76 (1985) 913-918
85. Becker A., Riefke B., Ebert B., Sukowski U., Rinneberg H., Semmler W., and Licha K. Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem. Photobiol. 72 (2000) 234-241
86. Sato Y., Yamauchi N., Takahashi M., Sasaki K., Fukaura J., Neda H., Fujii S., Hirayama M., Itoh Y., Koshita Y., Kogawa K., Kato J., Sakamaki S., and Niitsu Y. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J. 14 (2000) 2108-2118
87. Ryschich E., Huszty G., Knaebel H.P., Hartel M., Buchler M.W., and Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur. J. Cancer 40 (2004) 1418-1422
88. Qian Z., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharm. Rev. 54 (2002) 561-587
89. Hogemann-Savellano D., Bos E., Blondet C., Sato F., Abe T., Josephson L., Weissleder R., Gaudet J., Sgroi D., Peters P.J., and Basilion J.P. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5 (2003) 495-506
90. Antony A.C. Folate receptors. Annu. Rev. Nutr. 16 (1996) 501-521
91. Stephenson S.M., Low P.S., and Lee R.J. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol. 387 (2004) 33-50
92. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., and Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 52 (1992) 6708-6711
93. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski Jr. V.R., and Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52 (1992) 3396-3401
94. Sonvico F., Mornet S., Vasseur S., Dubernet C., Jaillard D., Degrouard J., Hoebeke J., Duguet E., Colombo P., and Couvreur P. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug. Chem. 16 (2005) 1181-1188
95. Okarvi S.M., and Jammaz I.A. Preparation and in vitro and in vivo evaluation of technetium-(99 m)-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother. Radiopharm. 21 (2006) 49-60
96. Quintana A., Raczka E., Piehler L., Lee I., Myc A., Majoros I., Patri A.K., Thomas T., Mule J., and Baker Jr. J.R. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19 (2002) 1310-1316
97. Choi Y., and Baker Jr. J.R. Targeting cancer cells with DNA-assembled dendrimers: a mix and match strategy for cancer. Cell Cycle 4 (2005) 669-671
98. Choi Y., Thomas T., Kotlyar A., Islam M.T., and Baker Jr. J.R. Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem. Biol. 12 (2005) 35-43
99. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., and Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6 (2000) 1949-1957
100. Stevens P.J., Sekido M., and Lee R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 21 (2004) 2153-2157
101. Cavallaro G., Mariano L., Salmaso S., Caliceti P., and Gaetano G. Folate-mediated targeting of polymeric conjugates of gemcitabine. Int. J. Pharm. 307 (2006) 258-269
102. Paranjpe P.V., Chen Y., Kholodovych V., Welsh W., Stein S., and Sinko P.J. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. J. Control. Release 100 (2004) 275-292
103. Arap W., Pasqualini R., and Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol. 10 (1998) 560-565
104. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., and Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5 (1999) 1032-1038
105. A. Signore, A. Annovazzi, M. Chianelli, F. Corsetti, C. Van de Wiele, R.N. Watherhouse, Peptide radiopharmaceuticals for diagnosis and therapy, Eur. J. Nucl. Med. 2001 Oct; 28(10):1555-65. 28 (2001) 1555-1565.
106. Giblin M.F., Veerendra B., and Smith C.J. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer. In Vivo 19 (2005) 9-29
107. Stolz B., Smith-Jones P., Albert R., Weckbecker G., and Bruns C. New somatostatin analogues for radiotherapy of somatostatin receptor expressing tumours. Ital. J. Gastroenterol. Hepatol. 1999 Suppl 2 (1999) S224-S226
108. Raja K.S., Wang Q., and Finn M.G. Icosahedral virus particles as polyvalent carbohydrate display platforms. Chem. Biol. Chem. 4 (2003) 1348-1351
109. Chen L., Zurita A.J., Ardelt P.U., Giordano R.J., Arap W., and Pasqualini R. Design and validation of a bifunctional ligand display system for receptor targeting. Chem. Biol. 11 (2004) 1081-1091
110. Tsao J., Chapman M.S., Agbandje M., Keller W., Smith K., Wu H., Luo M., Smith T.J., Rossmann M.G., Compans R.W., and Parrish C.R. The three-dimensional structure of canine parvovirus and its functional implications. Science 251 (1991) 1456-1464
111. Yuan W., and Parrish C.R. Canine parvovirus capsid assembly and differences in mammalian and insect cells. Virology 279 (2001) 546-557
112. Singh P., Destito G., Schneemann A., and Manchester M. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J. Nanobiotechnol. 4 (2006) 2
113. Parker J.S., Murphy W.J., Wang D., O'Brien S.J., and Parrish C.R. Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J. Virol. 75 (2001) 3896-3902
114. Young J.A.T. Virus entry and uncoating. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 87-104
115. Flenniken M.L., Liepold L.O., Crowley B.E., Willits D.A., Young M.J., and Douglas T. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem. Commun. (Cambridge) (2005) 447-449
116. Bachmann M., and Zinkernagel R. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15 (1997) 235-270
117. Bachmann M.F., Hengartner H., and Zinkernagel R.M. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction. Eur. J. Immunol. 25 (1995) 3445-3451
118. Green N.K., Herbert C.W., Hale S.J., Hale A.B., Mautner V., Harkins R., Hermiston T., Ulbrich K., Fisher K.D., and Seymour L.W. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11 (2004) 1256-1263
119. Maheshri N., Koerber J.T., Kaspar B.K., and Schaffer D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24 (2006) 198-204
120. Schiedner G., Clemens P.R., Volpers C., and Kochanek S. High-capacity gutless adenoviral vectors: technical aspects and applications. In: Curiel D.T., and Douglas J.T. (Eds). Adenoviral Vectors for Gene Therapy (2002), Academic Press, New York, USA 429-442
121. Schiedner G., Bloch W., Hertel S., Johnston M., Molojavyi A., Dries V., Varga G., Van Rooijen N., and Kochanek S. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum. Gene Ther. 14 (2003) 1631-1641
122. Ben-Gary H., McKinney R.L., Rosengart T., Lesser M.L., and Crystal R.G. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Molec. Ther. 6 (2002) 287-297
123. Christ M., Louis B., Stoeckel F., Dieterle A., Grave L., Dreyer D., Kintz J., Ali Hadji D., Lusky M., and Mehtali M. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum. Gene Ther. 11 (2000) 415-427
124. Muruve D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15 (2004) 1157-1166
125. Cotter M.J., and Muruve D.A. The induction of inflammation by adenovirus vectors used for gene therapy. Front. Biosci. 10 (2005) 1098-1105
126. Reid T., Warren R., and Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9 (2002) 979-986
127. Higginbotham J.N., Seth P., Blaese R.M., and Ramsey W.J. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther. 13 (2002) 129-141
128. Engler H., Machemer T., Philopena J., Wen S.F., Quijano E., Ramachandra M., Tsai V., and Ralston R. Acute hepatoxocity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328 (2004) 52-61
129. Hajitou A., Trepel M., Lilley C.E., Soghomonyan S., Alauddin M.M., Marini III F.C., Restel B.H., Ozawa M.G., Moya C.A., Rangel R., Sun Y., Zaoui K., Schmidt M., von Kalle C., Weitzman M.D., Gelovani J.G., Pasqualini R., and Arap W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125 (2006) 385-398